DALLAS, May 8, 2006 (PRIMEZONE) -- Tiens Biotech Group (USA), Inc. (AMEX:TBV) has been rated "Outperform," with a price target of $12.30 by Beacon Equity Research. The report is authored by Senior Research Analyst, Kris Goldcross, CFA.
The full report is available at http://www.beaconequityresearch.com
In the report Mr. Goldcross writes, "China-based Tiens Biotech Group, Inc. is a leading nutritional products company engaged in the research, development, manufacturing, and marketing of high quality nutritional supplements and wellness products both in China and in the international market. (The Company) has developed and is currently producing 39 nutrition supplements (including wellness products and dietary nutrition supplements) and 25 personal care products (including skin care products and personal washing products).
"The Company's herbal products, vitamins, mineral supplements, and personal care products are sold in over 31 provinces in China and in more than 90 countries across six continents.
"The Company's main competitors outside China include Amway, Avon, Mary Kay, Nu Skin Enterprises Inc., Herbalife Ltd., SunRider Corporation, Unicity Network and Morinda."
Beacon Equity Research Disclosure
The analysts contributing to this report do not hold any shares of Tiens Biotech Group (USA), Inc. (TBV). Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. The analyst(s) writing this report recognize and aspire to all of the CFA Institute Guidelines for Independent Research. Beacon Equity Research ("Beacon") certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analysts in the report. Beacon has received $6,000 from a non-controlling third party as compensation for this report. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change.
Anyone interested in receiving alerts regarding Tiens Biotech research should email members@beaconequityresearch.com with "TBV" in the subject line.